CO6210735A2 - Antagonistas de la ruta de hedgehog y aplicaciones terapeuticas de los mismos - Google Patents

Antagonistas de la ruta de hedgehog y aplicaciones terapeuticas de los mismos

Info

Publication number
CO6210735A2
CO6210735A2 CO10063835A CO10063835A CO6210735A2 CO 6210735 A2 CO6210735 A2 CO 6210735A2 CO 10063835 A CO10063835 A CO 10063835A CO 10063835 A CO10063835 A CO 10063835A CO 6210735 A2 CO6210735 A2 CO 6210735A2
Authority
CO
Colombia
Prior art keywords
branched
linear
cyclic
group
alkyl
Prior art date
Application number
CO10063835A
Other languages
English (en)
Inventor
Russell John Thomas
Mohr Gal La Pericot
Giacomo Minetto
Annette Cornelia Bakker
Pietro Ferruzzi
Original Assignee
Siena Biotech Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siena Biotech Spa filed Critical Siena Biotech Spa
Publication of CO6210735A2 publication Critical patent/CO6210735A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1.- Compuestos de Fórmula Iy sus sales aceptables para uso farmacéutico en donde, en tanto lo permitan la valencia y la estabilidad, R1 es H; un grupo alquilo (C1-C4) lineal, ramificado o cíclico, sustituido en forma opcional con uno o más halógeno, un grupo alcoxi (C1-C4) ramificado o lineal o un grupo mono- o di- alquilamino (C1-C6) lineal, ramificado o cíclico r es igual a cero, 1, 2 o 3; R1' representan, de manera independiente uno del otro cuando r>1, halógeno; un grupo alcoxi (C1-C4) lineal, ramificado o cíclico; un grupo alquilo (C1-C4) lineal, ramificado o cíclico sustituido en forma opcional con un grupo alcoxi, alquilamino, o dialquilamino (C1-C4) lineal o ramificado; R2 puede ser H, CI, F o Br X puede ser o N o CH i y j pueden ser 1, 2 o 3, la suma i+j no puede exceder 5, y cuando X es N, entonces i y j no pueden ser 1 R3 puede ser H; un grupo alquilo, oxaalquilo, alquilcarbonilo, alquilsulfonilo, oxaalquilcarbonilo, alcoxicarbonilo, alquilaminocarbonilo, oxaalquenilo, alquenilcarbonilo, oxaalquenilcarbonilo, alqueniloxicarbonilo, alquenilaminocarbonilo, alquilideno, alquiloxiimino, hidroxi, alcoxi, alqueniloxi (C1-C6) lineal, ramificado o cíclico, sustituido en forma opcional con carbamoilo o uno o más átomos de flúor; Ar; Ar-aminocarbonilo; un grupo alquilo, alquilamino, azaalquilo, oxaalquilo, alquilcarbonilo, alcoxicarbonilo o alquilaminocarbonilo (C1-C4) lineal o ramificado, sustituido con uno o dos Ar y sustituido en forma opcional con uno o más átomos de flúor;Q es tal que no se forma ningún enlace directo entre dos átomos de nitrógeno o entre un átomo de nitrógeno y un átomo de oxígeno y puede ser carbonilo; aminocarbonilo; carbonilamino, imina; SO2; ...
CO10063835A 2007-12-13 2010-05-27 Antagonistas de la ruta de hedgehog y aplicaciones terapeuticas de los mismos CO6210735A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07024218 2007-12-13

Publications (1)

Publication Number Publication Date
CO6210735A2 true CO6210735A2 (es) 2010-10-20

Family

ID=39432963

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10063835A CO6210735A2 (es) 2007-12-13 2010-05-27 Antagonistas de la ruta de hedgehog y aplicaciones terapeuticas de los mismos

Country Status (16)

Country Link
US (1) US8592463B2 (es)
EP (1) EP2227456A2 (es)
JP (1) JP5620821B2 (es)
CN (1) CN101896472A (es)
AR (1) AR069652A1 (es)
AU (1) AU2008335880B2 (es)
BR (1) BRPI0820856A2 (es)
CA (1) CA2709203A1 (es)
CO (1) CO6210735A2 (es)
CR (1) CR11481A (es)
EA (1) EA017918B1 (es)
IL (1) IL206298A0 (es)
NZ (1) NZ586121A (es)
TW (1) TW200930370A (es)
WO (1) WO2009074300A2 (es)
ZA (1) ZA201004185B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
CA2710858A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
MX2010006991A (es) * 2007-12-27 2010-09-30 Infinity Pharmaceuticals Inc Tratamientos de cancer terapeuticos.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2424840B1 (en) * 2009-04-27 2014-08-06 Boehringer Ingelheim International GmbH Cxcr3 receptor antagonists
CN102803246A (zh) * 2009-06-11 2012-11-28 锡耶纳生物技术股份公司 Hedgehog途径拮抗剂及其治疗应用
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
JP6141015B2 (ja) 2009-08-05 2017-06-07 インフィニティ ファーマスーティカルズ、インク． シクロパミン類似体の酵素によるアミノ基転移
US8952004B2 (en) 2010-01-07 2015-02-10 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
WO2011088404A1 (en) * 2010-01-15 2011-07-21 Infinity Pharmaceuticals , Inc Treatment of fibrotic conditions using hedgehog inhibitors
AU2011255218B2 (en) 2010-05-21 2015-03-12 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
EP2468726B1 (en) 2010-12-06 2013-08-28 Siena Biotech S.p.A. Compound for the treatment of tumours and tumour metastases
CA2824197C (en) 2011-01-10 2020-02-25 Michael Martin Processes for preparing isoquinolinones and solid forms of isoquinolinones
CA2842190A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
US9891149B2 (en) 2011-08-08 2018-02-13 Thermo Fisher Scientific Oy Method and apparatus for automated analysis
FI20115785A0 (fi) * 2011-08-08 2011-08-08 Thermo Fisher Scientific Oy Menetelmä ja laite automaattiseen analyysiin
AR091790A1 (es) 2011-08-29 2015-03-04 Infinity Pharmaceuticals Inc Derivados de isoquinolin-1-ona y sus usos
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2013052395A1 (en) 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. 1,3-substituted azetidine pde10 inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
CN103288803B (zh) * 2013-05-17 2017-10-31 郎恒元 苯并咪唑酰胺类化合物及其制备方法和应用
RU2019134551A (ru) 2013-05-30 2019-11-22 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
US9663499B2 (en) * 2013-06-07 2017-05-30 The California Institute For Biomedical Research Small molecule inhibitors of fibrosis
MX2016004340A (es) 2013-10-04 2016-08-08 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
FR3017867A1 (fr) * 2014-02-21 2015-08-28 Inventiva Nouveaux composes de type phenylazetidine carboxylate ou carboxamide
PT3119397T (pt) 2014-03-19 2022-04-11 Infinity Pharmaceuticals Inc Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
AU2015360583B2 (en) 2014-12-10 2020-01-23 The Scripps Research Institute Small molecule inhibitors of fibrosis
EP3302428A1 (en) 2015-06-04 2018-04-11 Pellepharm Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
WO2017139497A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Hedgehog inhibitor for use in relief of and treatment of pruritus or itching
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2018016227A (es) 2016-06-24 2019-07-08 Infinity Pharmaceuticals Inc Terapias de combinacion.
CN109232533A (zh) * 2017-09-28 2019-01-18 北京越之康泰生物医药科技有限公司 氮杂环类衍生物、其制备方法及其医药用途
WO2019062657A1 (zh) * 2017-09-30 2019-04-04 北京越之康泰生物医药科技有限公司 氮杂环类衍生物、其制备方法及其医药用途
CN110016054B (zh) * 2019-03-15 2021-10-22 四川大学 含磷氮苯并杂环结构的离子单体、用其阻燃的共聚酯型离聚物及它们的制备方法和应用
CN114790177B (zh) * 2021-01-26 2024-03-26 首都医科大学附属北京天坛医院 新型Hedgehog信号通路抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2349227C (en) * 1998-11-03 2008-02-05 Basf Aktiengesellschaft Substituted 2-phenylbenzimidazoles, the production thereof and their use
US7271261B2 (en) * 2001-10-19 2007-09-18 Ortho-Mcneil Pharmaceutical, Inc. Substituted benzimidazoles and imidazo-[4,5]-pyridines
EP2324830A1 (en) * 2002-03-05 2011-05-25 TransTech Pharma Inc. Process for the preparation of a monocyclic azole derivative that inhibits the interaction of ligands with rage
CN102803246A (zh) * 2009-06-11 2012-11-28 锡耶纳生物技术股份公司 Hedgehog途径拮抗剂及其治疗应用

Also Published As

Publication number Publication date
NZ586121A (en) 2012-03-30
JP5620821B2 (ja) 2014-11-05
CN101896472A (zh) 2010-11-24
TW200930370A (en) 2009-07-16
EA201000784A1 (ru) 2010-12-30
ZA201004185B (en) 2011-10-26
US20100286114A1 (en) 2010-11-11
IL206298A0 (en) 2010-12-30
WO2009074300A8 (en) 2009-11-19
AU2008335880B2 (en) 2014-03-13
WO2009074300A3 (en) 2009-10-01
CA2709203A1 (en) 2009-06-18
BRPI0820856A2 (pt) 2019-05-14
WO2009074300A2 (en) 2009-06-18
JP2011506366A (ja) 2011-03-03
EP2227456A2 (en) 2010-09-15
AR069652A1 (es) 2010-02-10
US8592463B2 (en) 2013-11-26
AU2008335880A1 (en) 2009-06-18
EA017918B1 (ru) 2013-04-30
CR11481A (es) 2010-10-15

Similar Documents

Publication Publication Date Title
CO6210735A2 (es) Antagonistas de la ruta de hedgehog y aplicaciones terapeuticas de los mismos
ES2570784T3 (es) Piridinas sustituidas como bloqueadores de los canales de sodio
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
CO5611128A2 (es) Compuestos derivados de n-aril-2-oxazolidinona-5-carboxamida como agentes antibacteriales
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
CO5630023A2 (es) Fenil quinolinas y su uso como agentes estrogenicos
MA38239A1 (fr) Nouveaux dérivés de pyridine
JP2013531029A5 (es)
AR068639A1 (es) Derivados de biarilo
MX2015010754A (es) Composiciones anti-suciedad con un polimero u oligomero que contiene un oxialquileno fluorado.
CO6741214A2 (es) Composiciones pesticidas y procesos relacionados
AR054790A1 (es) Metodos para el tratamiento de disfuncion sexual
AR053453A1 (es) Derivados de aminoalquil- y amidoalquil-benzopirano substituidos
CO6150146A2 (es) Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas su preparacion y su aplicacion en terapeutica
ES2534055T3 (es) Opioides de amina no fenólicos con sustituyentes de gran tamaño
AR054341A1 (es) Combinaciones sinergicas de compuestos activos fungicidas
MA38403A1 (fr) Nouveaux dérivés de pyrazole modulateurs specifiques de cb2
AR043831A1 (es) Derivados de pirrodilina y procedimiento para prepararlos
MX344276B (es) Compuesto de piperidina novedoso o sal del mismo.
AR056025A1 (es) Compuestos de imidazol sustituidos como inhibidores de ksp
ECSP088229A (es) Derivados de pirazolona como inhibidores de 11-beta hsd1
MX2009012377A (es) Compuestos de arilamida pirimidona.
RS54120B1 (en) Pyridinyl-I pyrazinyl-methyloxyaryl derivatives USED AS INHIBITORS OF TYROSINE KINASE TREATMENT (SYK)
PH12015501427A1 (en) Saturated nitrogen and n-acylated heterocycles potentiating the activity of an active antibiotic against mycobacteria

Legal Events

Date Code Title Description
FG Application granted